BenevolentAI SPAC Presentation Deck

Why BenevolentAl is the right fit for a combination with Odyssey Acquisition 2 4 Al-augmented drug discovery is at an inflection point, with the space increasingly a strategic area of focus for established Pharma companies. As one of the industry leaders, BenevolentAl is uniquely positioned to benefit from this paradigm shift BenevolentAl's platform has a proven track-record for tangible results and discoveries 3 • Identified PDE10 as an entirely novel target for the treatment of Ulcerative Colitis plus taken Atopic Dermatitis programme into clinic • Successfully identified Eli Lilly's Baricitinib as treatment for COVID-19 - now FDA Approved • Collaborating with AstraZeneca which has yielded first novel Al-generated target into AZ portfolio for CKD in January 2021 LO BenevolentAl combines a revolutionary Al-based drug discovery platform with advanced pharmaceutical development capabilities • Scientifically and commercially validated Al platform exploits a vast set of data points to identify truly novel drug targets across therapeutic areas and with a particular focus on complex diseases with material medical need • Advanced laboratory capabilities help move programmes faster, and generate data at scale for continuous innovation BenevolentAl benefits from a highly versatile, diversified and de-risked business model combining multiple therapeutic areas with the ability to develop in-house, to out-license or to collaborate with partners on new drug discovery and commercialisation BenevolentAl is led by an experienced management team with an outstanding track record in healthcare and technology, supported by industry-leading Board members and scientific advisors The investment opportunity represents an attractive value proposition with significant upside as evidenced by the extensive pipeline of drug candidates and the platform's potential Benevolent 6

View entire presentation